102 results about "Immune therapy" patented technology

Methods are disclosed related to identifying small molecule metabolites that serve as biomarkers of immune related adverse events (irAEs). In embodiments, treatments are disclosed that reduce the likelihood or prevent irAEs.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually.

The invention discloses a hepatocellular carcinoma prognosis and immune response prediction method based on multi-omics machine learning, and relates to the technical field of biomedicine and artificial intelligence crossing, and the method comprises the following steps: S1, constructing a multi-omics data set for model training and verification; s2, performing feature integration and clustering analysis on the multi-omics data to obtain corresponding hepatocellular carcinoma molecular subtype distribution; s3, constructing a hepatocellular carcinoma prognosis model based on Cox regression combined with a random survival forest, identifying 11 core immune genes and corresponding weight coefficients by training the model, and constructing an immunotherapy response index IMLIRI score; and S4, carrying out clinical application on the IMLIRI score. According to the method, through multi-omics data integration and multi-queue external verification, the influence of data deviation and queue heterogeneity on the model performance is reduced, so that the method shows stable prediction performance in hepatocellular carcinoma queues with different sources and different pathogenesis backgrounds, and the reliability and generalizability of the model in clinical application are improved.

Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one CD122 / CD132 agonist, at least one immune checkpoint inhibitor and a viral composition comprising one or more viruses engineered to overexpress a tumor suppressor gene and / or an adenoviral death protein. Also provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one oncolytic viral composition and at least one CD122 / CD132 agonist and at least one immune checkpoint inhibitor. Also provided herein are methods of enhancing anti-tumor efficacy by administering the agents described above in combination with other cancer therapies. In highly aggressive forms of cancer, known to be generally resistant to immune therapies, these treatments unexpectedly resulted in complete tumor remissions and curative outcomes.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.

This disclosure generally relates to a molecular classification of cancer and particularly to molecular markers for predicting response to cancer therapy, including cancer immune therapy, and methods of use thereof.

To provide systems and methods for histotripsy and immune therapies.SOLUTION: In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.SELECTED DRAWING: Figure 1

The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

This invention discloses an antibody-engineered bone marrow stromal cell and its applications, belonging to the field of biomedical technology. Using bone marrow stromal cells as a biological carrier, this invention externally modifies them with immune checkpoint antibodies to form an antibody-coated engineered cell preparation, thereby achieving targeted and precise mitochondrial delivery of exhausted T cells. This cell preparation can be used in combination with other immunotherapies that can induce T cell exhaustion, such as tumor immunotherapies and CAR-T therapy, to help enhance their anti-tumor efficacy and duration of effect.

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical / therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector / substrate / support / scaffold for direct application.

Disclosed herein are methods of preventing or reducing the development of colorectal cancer in a subject identified as at risk of colorectal tumorigenesis. The methods include administering to the subject a composition comprising a zwitterionic capsular polysaccharide derived from a Bacteroides uniformis bacteria in an amount effective to prevent or reduce the development of colorectal cancer. Methods of treating colorectal cancer, reducing tumor size or tumor growth, inducing Natural Killer cell activity, and inducing Lag- 3 on Natural Killer cells are also provided.

Provided are compositions and methods for treating Lewis Y antigen positive cancers in mammalian subjects by administering an effective amount of a radionuclide-labeled Lewis Y antigen targeting agent such as an antibody labeled with an alpha particle-emitting radionuclide such as 225Ac. The methods may further include administration of additional agents, such as radiosensitizing agents, immune checkpoint therapies, CD47 blockades, and / or DNA damage response inhibitors.

The present invention relates to an animal model for research on cancer immunotherapy agents, and a preparation method therefor. A nude mouse, which is a mouse model widely used for evaluating the effects of anticancer agents, can verify the efficacy of a cytotoxic anticancer agent, but cannot confirm the effect of an cancer immunotherapy agent because immune function is deficient. However, a cancer animal model according to the present invention has normal immune function, thereby enabling preclinical efficacy of a cancer immunotherapy agent to be accurately predicted, and thus is expected to contribute to improving the prognosis of a patient for whom surgery is not possible.

The invention relates to the technical field of biomedical engineering, and discloses a detection method for esophageal squamous carcinoma CTC enrichment and immunotherapy curative effect dynamic evaluation, and the method utilizes a micro-fluidic chip to carry out electrical impedance detection and physical preliminary screening on cells in a whole blood sample. And performing anti-reclosing time sequence verification on the screened interstitial circulating tumor cells, triggering transient flow resistance regulation and control when conditions are met, and opening a lateral shunt channel to reduce the flow velocity of a main flow channel. And meanwhile, the adaptive optical imaging unit is synchronously switched to a long integral time mode to collect a fluorescence image. And finally, the data calculation terminal calculates an immunotherapy curative effect evaluation index in combination with cell counting, an omission compensation item and PD-L1 expression intensity. Through synchronous linkage of the flow velocity and exposure, the problem of weak fluorescence signal detection under high-speed flow is solved, and the evaluation accuracy is improved.

The invention belongs to the technical field of immunotherapy of allergic diseases, and provides a method for identifying dominant B cell epitopes and T cell epitopes in wheat omega-5 prolamin. According to the identification method provided by the invention, an immunoinformatics tool, a proliferation test, a degranulation test and the like are comprehensively applied, and the cell proliferation capacity, cell factor release, IgG / IgE binding capacity and degranulation capacity of T / B cell epitopes are evaluated. Results show that the T cell epitopes T1 and T2 sharing the same sequence are relatively strong in multiplication capacity, can up-regulate Th2 related cell factors, but do not have degranulation activity. Three B cell peptide fragments B3, B4 and B9 which share a common motif region QQXPQQQ (X = F, L) can promote IgG / IgE binding and degranulation capabilities. These findings would contribute to the development of epitope-based immunotherapies against wheat allergy individuals.

This invention relates to compositions comprising an immunogen and a manganese glycerophosphate (MnGp) gel useful in raising an immune response in a subject, vaccinating a subject, and / or immunotherapy, such as cancer immunotherapy, in a subject. In addition, this invention relates to MnGp gels and methods of synthesizing the same using mechanical shear stress and / or synthesis of nanoparticles.

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

This disclosure contemplates methods of detecting, measuring, and / or quantifying a tensional force on cells that express an antigen. In certain embodiments, this disclosure relates to methods and devices disclosed herein used to determine or monitor whether a cancer therapy or other immunotherapy is appropriate for a specific patient. In certain embodiments, the therapy is administering blinatumomab or other bispecific engager to a patient.

Provided are pharmaceutical compositions for reducing a tumor burden in a subject having a cancer comprising a combination therapy comprising a therapeutically effective dose of a modified CD2 polypeptide derived from human or rat domain one of CD2 polypeptide and a second therapeutic agent comprising an immune checkpoint inhibitor. Also provided are methods of inhibiting or reducing tumor growth and methods of synergistically increasing the activity of an anti-PD-L1 immunotherapeutic in a subject having a cancer comprising administering the pharmaceutical compositions.

The invention belongs to the technical field of traditional Chinese medicine. More specifically, the invention relates to a traditional Chinese medicine composition for synergistically enhancing the anti-hepatoma curative effect of a PD-1 inhibitor and reducing toxic and side effects and application of the traditional Chinese medicine composition. The research finds that the traditional Chinese medicine composition and a PD-1 inhibitor are combined for use, so that a remarkable anti-tumor effect can be generated. Clinical research proves that when the traditional Chinese medicine composition is combined with the PD-1 inhibitor, the objective remission rate can be increased, clinical symptoms (such as liver region pain, weakness and poor appetite) of patients can be improved, the life quality can be further improved, and meanwhile, the adverse reaction related to immunotherapy can be effectively reduced. The traditional Chinese medicine composition provided by the invention solves the clinical problems of low effective rate and large toxic and side effects of PD-1 inhibitor single-drug treatment through a multi-target regulation effect, provides a safer and more effective scheme for immunotherapy of liver cancer, and has good clinical application prospects and popularization values.

The present disclosure relates to methods and systems for predicting a subject's responsiveness to treatment or therapy. Specifically, the methods and systems provided herein may predict whether a subject suffering from disease or cancer may respond to immune therapy, including treatment with an immune checkpoint inhibitor such as agonist anti-CD137 antibodies, PD-1 antagonists, anti-CTL4 antibodies, or any combination thereof.

To provide methods and compositions for sensitization of tumor cells to immune therapy.SOLUTION: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject having cancer) by administering to the subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of composition related to methods of sensitizing a cancer cell to tumor necrosis factor alpha (TNF-α)- mediated killing by contacting the cancer cell or administering an agent that inhibits autophagy. Provided herein are methods and compositions for increasing the sensitivity of cancer cells to T cell killing (e.g., tumor necrosis factor-α (TNF -α)- mediated killing) by inhibiting autophagy and / or the NF-κB pathway.SELECTED DRAWING: None

The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. It was found that responders of immunotherapeutic treatments have a higher amount of B-cell exosomes in their blood than non-responders. Aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after B-cell exosomes have been detected in a biological sample from the subject.

Compounds for the prevention and treatment of cancer have a first binding peptide from a urokinase-type plasminogen receptor (uPAR) antagonist operatively linked to an antibody peptide operatively linked to a second binding peptide from an endostatin or plasminogen derived peptide sequence.

The invention discloses a pharmaceutical composition containing a polysialic acid-melittin polyion compound and sialic acid modified anthracycline anti-tumor drug liposome and application of the pharmaceutical composition. The invention belongs to the technical field of biological medicine, and particularly relates to a targeted delivery pharmaceutical composition for treating cold tumors through immunotherapy, and the pharmaceutical composition comprises a polysialic acid-melittin polyion compound and sialic acid modified anthracycline antitumor drug liposome. The anthracycline antitumor drug is selected from one or more of the following components: doxorubicin, epirubicin, pirarubicin, idarubicin, daunorubicin or mitoxantrone. The pharmaceutical composition shows a remarkable synergistic effect in tumor inhibition index, can stimulate congenital immunity and adaptive immunity, induce multiple release of tumor-associated antigens and specific antigens, trigger tumor immune circulation and recover immune control of a body on tumors, and also can enable the body to generate immune memory, so that the tumor inhibition effect is improved. And a new combined treatment strategy is provided for cold tumor treatment.

The invention discloses an engineering fibroblast as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the engineering fibroblast provided by the invention, a proinflammatory factor IL-1 is neutralized by secreting IL-1RA, an inflammatory loop mediated by the proinflammatory factor IL-1 is broken, and a tumor immune microenvironment is remodeled, so that inhibition on immune effector cells (such as T cells and NK cells) is indirectly and effectively relieved, and favorable conditions are created for other immunotherapy methods or body autoimmune clearance; the problem that the immunosuppressive tumor microenvironment cannot be regulated and controlled well is solved. Meanwhile, the defects that the half-life period of the recombinant IL-1RA protein is short, frequent administration is needed, the local drug concentration of the focus is difficult to maintain and the like are overcome, stable and high-concentration delivery of the therapeutic protein is realized, and the pharmacokinetic bottleneck of the traditional protein drug is overcome.